ICICI Direct: Aurobindo Pharma Posts In-Line Q2 Numbers With Better Gross Margins  
A man rides past an Aurobindo Pharma Ltd. production facility in Jadcherla, India. (Photographer: Prashanth Vishwanathan/Bloomberg)

ICICI Direct: Aurobindo Pharma Posts In-Line Q2 Numbers With Better Gross Margins  

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Aurobindo Pharma Ltd.’s revenues grew 15.8% YoY to Rs 6,483 crore (our estimate Rs 6,386 crore) mainly due to 12.5% YoY growth in U.S. to Rs 3,190 crore.

Europe business grew 8.1% YoY to Rs 1,515 crore.

Anti-retroviral segment grew 111.3% YoY to Rs 503 crore. Rest of World markets also posted robust growth of 39.9% YoY to Rs 447 crore.

Ebitda margins grew 174 basis points YoY to 22.1% (our estimate 20.6%) with higher gross margins being partly offset by higher other expenditure.

Click on the attachment to read the full report:

ICICI Direct Aurobindo Q2FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.